摘要
目的研究心肌梗死患者应用瑞舒伐他汀和辛伐他汀对血清C反应蛋白(CRP)、基质金属蛋白酶-9(MMP-9)水平的影响。方法 86例心肌梗死患者,随机分为甲组和乙组,各43例。甲组患者采用瑞舒伐他汀治疗,乙组患者采用辛伐他汀治疗。比较两组患者治疗前后血清CRP、MMP-9水平。结果治疗前,两组患者CRP、MMP-9水平比较差异无统计学意义(P>0.05);治疗后,甲组患者血清CRP为(2.05±0.32)mg/L、MMP-9为(110.5±12.8)ng/L,均低于乙组的(3.12±0.47)mg/L、(143.7±15.3)ng/L,差异具有统计学意义(P<0.05)。结论在心肌梗死的临床治疗中,瑞舒伐他汀能起到更好的清除炎症因子、降低MMP-9水平的效果,有助于促进患者的康复,值得推广应用。
Objective To research influence by rosuvastatin and simvastatin on serum C-reactive protein（CRP） and matrix metalloproteinase-9（MMP-9） levels in myocardial infarction patients. Methods A total of 86 patients with myocardial infarction were randomly divided into group A and group B, with 43 cases in each group. Group A received rosuvastatin for treatment, and group B received simvastatin for treatment. Comparison was made on serum CRP and MMP-9 levels before and after treatment between the two groups. Results Before treatment, there was no statistically significant difference of CRP and MMP-9 levels between the two groups（P0.05）. After treatment, group A had serum CRP as（2.05±0.32） mg/L and MMP-9 as（110.5±12.8） ng/L, which were all lower than（3.12±0.47） mg/L and（143.7±15.3） ng/L in group B, and their difference had statistical significance（P0.05）. Conclusion In clinical treatment of myocardial infarction, rosuvastatin provides better effect in eliminating inflammatory factor and reducing MMP-9 level. It is helpful to accelerate rehabilitation in patients, and it is worth promoting and applying.
出处
《中国实用医药》
2017年第5期115-117,共3页
China Practical Medicine
